title: Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
abstract: The aim of this study is to evaluate oral administration of poly (butylcyanoacrylate) nanoparticulate delivery systems (PBCA-NDSs), double-coated with Tween 80 and poly (ethylene) glycol (PEG) 20000 for brain delivery of hexapeptide dalargin, an anti-nociceptive peptide that does not cross blood-brain barrier (BBB) by itself. Studies have proven the brain uptake of Tween 80 overcoated nanoparticles after intravenous administration, but studies for brain delivery of nanoparticles after oral administration had been limited due to reduced bioavailability of nanoparticles and extensive degradation of the peptide and/or nanoparticles by gastrointestinal enzymes. To address this problem, dalargin-loaded PBCA-NDS were successively double-coated with Tween 80 and PEG 20000 in varied concentrations of up to 2% each. Measurement of in vivo central anti-nociceptive effect of dalargin along with a dose response curve was obtained by the tail flick test following the oral administration of PBCA-NDSs to mice. Results from the tail flick test indicated that significant dalargin-induced analgesia was observed from PBCA-NDSs with double-coating of Tween and PEG in comparison with single-coating of either Tween or PEG. Hence, it could be concluded that surface coated PBCA-NDS can be used successfully for brain targeting of dalargin or other peptides administered orally. However, further studies are required to elucidate the exact transport mechanism of PBCA-NDSs from gastrointestinal tract to brain.
authors.affiliation: College of Pharmacy and Allied Health Professions, St. John's University, Jamaica, NY 11439, USA.
authors.forename: Debanjan
authors.initials: D
authors.lastname: Das
authors.forename: Senshang
authors.initials: S
authors.lastname: Lin
mesh_terms: D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage*; D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D004355:Drug Stability; D004659:Enbucrilate / Q000008:administration & dosage*; D016308:Enkephalin, Leucine-2-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D051379:Mice; D049329:Nanostructures; D011092:Polyethylene Glycols / Q000008:administration & dosage; D012995:Solubility
chemical_list: D000700:Analgesics; D011092:Polyethylene Glycols; D016308:Enkephalin, Leucine-2-Alanine; D004659:Enbucrilate; C040996:enkephalin-Leu, Ala(2)-Arg(6)-